SCHEMBL5396336

SCHEMBL5396336

CC(=O)Oc1cc(Cl)c(Oc2ccc(N)c([N+](=O)[O-])c2)c(Cl)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
LMNA P02545 5/20 0.39
MAPT P10636 5/20 0.39
ALDH1A1 P00352 4/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MITF O75030 1/20 0.39
CCR6 P51684 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
POLB P06746 3/20 0.38
TDP1 Q9NUW8 3/20 0.37
HPGD P15428 2/20 0.37
RAF1 P04049 1/20 0.37
MAPK1 P28482 1/20 0.37
GFER P55789 1/20 0.37
PAX8 Q06710 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5382492 0.85 MEN1 (0.46) LMNAMAPTALDH1A1HTTSMN1; SMN2
SCHEMBL5385584 0.85 ICAM1 (0.35) TSHRLMNAMAPTALDH1A1HTT
SCHEMBL5388204 0.85 NR4A1 (0.39) LMNAMAPTHTTPOLBMAPK1
SCHEMBL5388191 0.82 TDP1 (0.42) TSHRLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL5386437 0.82 THRA (0.38) LMNAHTTMEN1KMT2APOLB
SCHEMBL5389109 0.81 CYP19A1 (0.39) TSHRLMNAMAPTALDH1A1HTT
SCHEMBL5393453 0.80 BRAF (0.37) MAPTALDH1A1HPGDRAF1
SCHEMBL9370719 0.76 TSHR (0.53) TSHRLMNAMAPTALDH1A1HTT
SCHEMBL7120745 0.75 ALDH1A1 (0.38) LMNAMAPTALDH1A1HTTSMN1; SMN2
SCHEMBL7114898 0.75 MAPT (0.43) TSHRLMNAMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199265-B2 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones KARO BIO AB (SE) 2007-04-03 US disclosed
US-20040097589-A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones KARO BIO AB (SE) 2004-05-20 US disclosed
EP-1296936-A1 THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES KARO BIO AB (SE) 2003-04-02 EP disclosed
WO-2001098256-A1 THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES KARO BIO AB (SE) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097589-A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones TSHR, THRA, THRB TSHR 1/4885LMNA 3427/4885MAPT 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.